#oncology

RT @MiguelHernan: 1/

Problem: The best therapies for advanced pancreatic #cancer (Folfirinox, GN) haven't been compared in a head-to-head randomized trial due to cost and commercial barriers.

We emulated a #TargetTrial using observational data: Folfirinox is a bit better

https://www.sciencedirect.com/science/article/pii/S1047279722003088?dgcid=coauthor

The reflex to indiscriminately stratify and adjust on covariates is strong in biomedical research. I face this so often, especially with clinician-scientist collaborators.

The analyses and models that arise from this, in fact, often do not well represent how exposures and treatments exert their effect in reality.

A #TargetTrial approach crystallizes when, where, and how co-variates should be treated.

Take this great illustration from Target Trial originator @MiguelHernan where he explains the study design choices for study on COVID vaccine booster effectiveness:

https://fediscience.org/@MiguelHernan/109331025655365201

#epidemiology #biostatistics #epitwitter #statstodon #epiVerse @epiVerse